Статья

17 Авг 2006

Daniel Rosan, Program Director for Public Health, Interfaith Center on Corporate Responsibility [USA]

[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

[identifies pharmaceutical best practice in key areas including research, paediatric needs, drug accessibility, reporting, philanthropy, political engagement; rates 15 top pharmaceutical firms on each practice: Abbott Laboratories, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences, Johnson & Johnson, Eli Lilly, Merck, Novartis, Pfizer, Hoffmann-La Roche (part of Roche), sanofi-aventis, Schering-Plough, Wyeth]

Хронология

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Дата:

4 Мар 2014

Тип содержимого:

Ответ компании

Доступные языки: English
[PDF] Benchmarking AIDS: 2006 Year End Update

Дата:

30 Ноя 2006

Тип содержимого:

Статья

Доступные языки: English
Response by Merck: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Merck - finds none has comprehensive approach.

Дата:

13 Сен 2006

Тип содержимого:

Ответ компании

Доступные языки: English
Response by Wyeth (part of Pfizer): Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Wyeth - finds none has comprehensive approach.

Дата:

13 Сен 2006

Тип содержимого:

Ответ компании

Доступные языки: English
Response by Bristol-Myers Squibb: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Bristol-Myers Squibb - finds none has comprehensive approach.

Дата:

13 Сен 2006

Тип содержимого:

Ответ компании

Доступные языки: English
Company responses to Interfaith Center on Corporate Responsibility report "Benchmarking AIDS"

Дата:

12 Сен 2006

Тип содержимого:

Статья

Доступные языки: English
Response by Boehringer Ingelheim: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Boehringer-Ingelheim - finds none has comprehensive approach.

Дата:

6 Сен 2006

Тип содержимого:

Ответ компании

Доступные языки: English
Response by AstraZeneca: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including AstraZeneca - finds none has comprehensive approach.

Дата:

6 Сен 2006

Тип содержимого:

Ответ компании

Доступные языки: English
Reclaman mayor compromiso de las farmacéuticas

Дата:

31 Авг 2006

Тип содержимого:

Статья

Доступные языки: español
Eli Lilly did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Eli Lilly - finds none has comprehensive approach.

Дата:

23 Авг 2006

Тип содержимого:

Ответ компании

Доступные языки: English
Response by Pfizer: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Pfizer - finds none has comprehensive approach.

Дата:

23 Авг 2006

Тип содержимого:

Ответ компании

Доступные языки: English
Response by Novartis: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Novartis - finds none has comprehensive approach.

Дата:

23 Авг 2006

Тип содержимого:

Ответ компании

Доступные языки: English
International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

Дата:

17 Авг 2006

Тип содержимого:

Статья

Доступные языки: English
[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

Дата:

17 Авг 2006

Тип содержимого:

Статья

Доступные языки: English
New Report: Top pharma companies fail to address industry best practices on HIV/AIDS

Дата:

14 Авг 2006

Тип содержимого:

Статья

Доступные языки: English
Sanofi-Aventis did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including sanofi-aventis - finds none has comprehensive approach.

Дата:

1 Авг 2006

Тип содержимого:

Ответ компании

Доступные языки: English
Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Дата:

1 Авг 2006

Тип содержимого:

Ответ компании

Доступные языки: English
Hoffmann-La Roche (part of Roche) did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Hoffman-La Roche - finds none has comprehensive approach.

Дата:

8 Янв 2006

Тип содержимого:

Ответ компании

Доступные языки: English
Gilead Sciences did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Gilead - finds none has comprehensive approach.

Дата:

8 Янв 2006

Тип содержимого:

Ответ компании

Доступные языки: English

См. полную историю

Загрузить еще См. меньше

Business & Human Rights
Resource Centre

Ресурсный центр по вопросам бизнеса и прав человека

Эта страница недоступна на Русский и отображается на English

[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

Хронология

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

[PDF] Benchmarking AIDS: 2006 Year End Update

Response by Merck: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Merck - finds none has comprehensive approach.

Response by Wyeth (part of Pfizer): Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Wyeth - finds none has comprehensive approach.

Response by Bristol-Myers Squibb: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Bristol-Myers Squibb - finds none has comprehensive approach.

Company responses to Interfaith Center on Corporate Responsibility report "Benchmarking AIDS"

Response by Boehringer Ingelheim: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Boehringer-Ingelheim - finds none has comprehensive approach.

Response by AstraZeneca: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including AstraZeneca - finds none has comprehensive approach.

Reclaman mayor compromiso de las farmacéuticas

Eli Lilly did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Eli Lilly - finds none has comprehensive approach.

Response by Pfizer: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Pfizer - finds none has comprehensive approach.

Response by Novartis: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Novartis - finds none has comprehensive approach.

International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

New Report: Top pharma companies fail to address industry best practices on HIV/AIDS

Sanofi-Aventis did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including sanofi-aventis - finds none has comprehensive approach.

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Hoffmann-La Roche (part of Roche) did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Hoffman-La Roche - finds none has comprehensive approach.

Gilead Sciences did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Gilead - finds none has comprehensive approach.